Castleman Disease Treatment Market by Disease Type (Multicentric Castleman’s Disease, Unicentric Castleman’s Disease), Indication (Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor), Treatment, Application - Global Forecast 202

Castleman Disease Treatment Market by Disease Type (Multicentric Castleman’s Disease, Unicentric Castleman’s Disease), Indication (Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor), Treatment, Application - Global Forecast 2024-2030


The Castleman Disease Treatment Market size was estimated at USD 294.33 million in 2023 and expected to reach USD 334.15 million in 2024, at a CAGR 13.62% to reach USD 719.87 million by 2030.

Castleman disease treatment involves a specialized healthcare procedure to manage a rare illness called Castleman disease, which is characterized by the overgrowth of cells in the body's lymph nodes, causing a variety of symptoms from fever and fatigue to abnormal weight loss. Recent years have observed an increased prevalence of rare diseases, including Castleman disease, necessitating enhanced treatment options. The understanding of Castleman disease has advanced over the years, leading to the development of targeted therapies. Ongoing research focuses on identifying biomarkers, understanding the underlying pathophysiology, and discovering novel treatment options. Some treatments for Castleman disease have received orphan drug designation, which provides incentives for pharmaceutical companies to develop therapies for rare diseases. However, the high cost of drug development, limited treatment options, and strict regulatory compliance impede the expansion of treatment. Healthcare professionals, researchers, and advocacy groups are collaborating on a global scale to improve the diagnosis, management, and treatment of Castleman disease.

Regional Insights

The Americas, particularly the U.S. and Canada, has a relatively well-established infrastructure for rare disease diagnosis and treatment, including Castleman disease. There are specialized medical centers and experts focused on the condition, and patient advocacy groups and research institutes have contributed to the awareness and advancements in diagnosis and treatment. In Asia, access to castle treatment is limited when compared to the other regions; however, the government investment in healthcare development has significantly strived toward a more focused approach to rare diseases. Major cities in the region offer advanced diagnostic and treatment options, and small-scale academic institutes in China, Japan, and India are investing heavily in R&D activities. In Europe, the government promotes stakeholder cooperation in healthcare and research activities, benefiting the treatment of Castleman disease. The European Medicines Agency has been working on reviewing improved medications and approving them to elevate the provision and access to Castleman treatment to patients in the region.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Castleman Disease Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
  • Prevalence of Castleman disease and the need for effective disease management
  • Provision of orphan drug designation and approvals for Castleman disease treatments
  • Rise of patient advocacy groups and awareness programs for Castleman treatment
Market Restraints
  • Complexities in the drug development for Castleman disease
Market Opportunities
  • Ongoing advancements in the development of new Castleman disease treatment
  • Emerging trend of personalized medicine for Castleman disease treatment
Market Challenges
  • Lack fo standardized treatment protocols
Market Segmentation Analysis
  • Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman’s disease due to the chances of systemic organ failure
  • Indication: Rising adoption of Castlemann’s disease treatment options for tackling angiomatous lymphoid cases
  • Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
  • Application: Preference for ambulatory surgical centers due to provision of optimum patient care
Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Castleman Disease Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Castleman Disease Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Tocilizumab Biosimilar Tofidence

The US Food and Drug Administration (FDA) approved Tofidence (tocilizumab-bavi) as the first biosimilar to Actemra (tocilizumab). Tofidence was developed through a partnership between Biogen and Bio-Thera Solutions. Tocilizumab is a monoclonal antibody that targets IL-6R, an immunosuppressant drug used for treating rheumatoid arthritis and systemic juvenile idiopathic arthritis in children. It is also approved for Castleman's disease, a rare benign tumor of B cells, in Japan. This approval signifies an important advancement in the treatment options available for Castleman's disease.

Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan

Chugai Pharmaceutical Co., Ltd. received approval from the Japanese Ministry of Health, Labour and Welfare for an additional indication of treatment of Castleman Disease with their humanized anti-human IL-6 receptor monoclonal antibody, Actemra Intravenous Infusion. This expands the original indication for treating cytokine release syndrome induced by tumor-specific T-cell infusion therapy to incorporate other cancer treatments.

Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases

Medable Inc., a technology platform for patient-centered clinical trials, partnered with Every Cure, a non-profit organization established in collaboration with the Clinton Global Initiative. The objective of this partnership is to identify potential treatments for rare conditions, including Castleman disease.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Castleman Disease Treatment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disease Type
  • Multicentric Castleman’s Disease
  • Unicentric Castleman’s Disease
  • Indication
  • Angiofollicular Lymph Node Hyperplasia
  • Angiomatous Lymphoid
  • Castleman Tumor
  • Giant Benign Lymphoma
  • Giant Lymph Node Hyperplasia
  • Hamartoma of the Lyphatics
  • Treatment
  • Antiviral Drugs
  • Chemotherapy
  • Corticosteroids
  • Immunotherapy
  • Monoclonal Antibodies
  • Radiation Therapy
  • Application
  • Ambulatory Surgical Centers
  • Hospitals
Region
  • Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom


Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of Castleman disease and the need for effective disease management
5.1.1.2. Provision of orphan drug designation and approvals for Castleman disease treatments
5.1.1.3. Rise of patient advocacy groups and awareness programs for Castleman treatment
5.1.2. Restraints
5.1.2.1. Complexities in the drug development for Castleman disease
5.1.3. Opportunities
5.1.3.1. Ongoing advancements in the development of new Castleman disease treatment
5.1.3.2. Emerging trend of personalized medicine for Castleman disease treatment
5.1.4. Challenges
5.1.4.1. Lack fo standardized treatment protocols
5.2. Market Segmentation Analysis
5.2.1. Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman’s disease due to the chances of systemic organ failure
5.2.2. Indication: Rising adoption of Castlemann’s disease treatment options for tackling angiomatous lymphoid cases
5.2.3. Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
5.2.4. Application: Preference for ambulatory surgical centers due to provision of optimum patient care
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Castleman Disease Treatment Market, by Disease Type
6.1. Introduction
6.2. Multicentric Castleman’s Disease
6.3. Unicentric Castleman’s Disease
7. Castleman Disease Treatment Market, by Indication
7.1. Introduction
7.2. Angiofollicular Lymph Node Hyperplasia
7.3. Angiomatous Lymphoid
7.4. Castleman Tumor
7.5. Giant Benign Lymphoma
7.6. Giant Lymph Node Hyperplasia
7.7. Hamartoma of the Lyphatics
8. Castleman Disease Treatment Market, by Treatment
8.1. Introduction
8.2. Antiviral Drugs
8.3. Chemotherapy
8.4. Corticosteroids
8.5. Immunotherapy
8.6. Monoclonal Antibodies
8.7. Radiation Therapy
9. Castleman Disease Treatment Market, by Application
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
10. Americas Castleman Disease Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Castleman Disease Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Castleman Disease Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. FDA Approves Tocilizumab Biosimilar Tofidence
13.3.2. Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
13.3.3. Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings